9 Meters Biopharma, Inc.
9 Meters Biopharma, Inc., headquartered in the United States, is a pioneering biotechnology company focused on developing innovative therapies for patients with rare gastrointestinal diseases. Founded in 2018, the company has quickly established itself in the biopharmaceutical industry, particularly in the areas of drug development and clinical research.
With a robust pipeline that includes unique oral therapies, 9 Meters Biopharma is dedicated to addressing unmet medical needs in conditions such as short bowel syndrome and celiac disease. Their flagship product, a novel treatment for short bowel syndrome, showcases their commitment to advancing patient care through cutting-edge science.
Recognised for its rapid progress and strategic partnerships, 9 Meters Biopharma is positioned as a leader in the biopharma sector, striving to improve the quality of life for patients worldwide.
-20 vs industry average
9 Meters Biopharma, Inc.’s score of 18 is lower than 31% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at 9 Meters Biopharma, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for 9 Meters Biopharma, Inc. yet.
9 Meters Biopharma, Inc.'s reported carbon emissions
9 Meters Biopharma, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in the latest emissions data. Consequently, there are no recorded Scope 1, Scope 2, or Scope 3 emissions totals available for analysis.
Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards. This lack of data suggests that 9 Meters Biopharma may still be in the early stages of developing its climate strategy or reporting framework.
As the biopharmaceutical industry increasingly prioritises sustainability and carbon reduction, 9 Meters Biopharma's future commitments and initiatives will be crucial for aligning with industry standards and addressing climate change effectively.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
9 Meters Biopharma, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for 9 Meters Biopharma, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
9 Meters Biopharma, Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project